Autonomix Medical has been issued U.S. Patent No. 12,471,776, strengthening its intellectual property portfolio for precision neuromodulation. The patent covers systems, devices, and methods for monitoring physiologic signals to assess autonomic nervous system activity, including technologies for evaluating sympathetic and parasympathetic function through multiple assessment techniques. It also encompasses innovations that may support patient selection, procedural guidance, treatment feedback, and post-treatment monitoring across a broad range of neuromodulation applications. CEO Brad Hauser stated the patent protects innovations designed to improve the precision and effectiveness of future nerve-targeted therapies, reinforcing the company's vision of building a differentiated technology platform for diseases involving the peripheral nervous system.
Autonomix Medical, Inc. Common StockSecured a new U.S. patent covering systems and methods for autonomic nervous system assessment, strengthening IP portfolio for precision neuromodulation.